• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514).

作者信息

Soussain Carole, Malaise Denis, Choquet Sylvain, Ghesquières Hervé, Houillier Caroline

机构信息

Hematology, Institut Curie, Site Saint-Cloud, Saint-Cloud, France.

Ophthalmology, Institut Curie, Site Paris, Université Paris V Descartes et PSL (Paris Science et Lettre), Paris, France.

出版信息

Eur J Cancer. 2023 Aug;189:112909. doi: 10.1016/j.ejca.2023.04.025. Epub 2023 Jun 8.

DOI:10.1016/j.ejca.2023.04.025
PMID:37301714
Abstract
摘要

相似文献

1
Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514).伊布替尼单药治疗复发或难治性原发性中枢神经系统淋巴瘤（PCNSL）和原发性玻璃体视网膜淋巴瘤（PVRL）后的持久完全缓解：淋巴瘤研究协会（LYSA）和法国眼脑淋巴瘤（LOC）网络进行的iLOC研究的长期结果（临床试验编号：NCT02542514）
Eur J Cancer. 2023 Aug;189:112909. doi: 10.1016/j.ejca.2023.04.025. Epub 2023 Jun 8.
2
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.伊布替尼单药治疗复发或难治性原发性中枢神经系统淋巴瘤和原发性玻璃体视网膜淋巴瘤：淋巴瘤研究协会 (LYSA) 和法国眼脑淋巴瘤 (LOC) 网络进行的 II 期“概念验证”iLOC 研究的最终分析。
Eur J Cancer. 2019 Aug;117:121-130. doi: 10.1016/j.ejca.2019.05.024. Epub 2019 Jul 3.
3
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.硼替佐米和地塞米松治疗复发/难治性原发性中枢神经系统或玻璃体视网膜淋巴瘤的 1 期研究。
Blood. 2018 Nov 22;132(21):2240-2248. doi: 10.1182/blood-2018-02-835496. Epub 2018 Sep 27.
4
Primary vitreoretinal lymphoma: short review of the literature, results of a European survey and French guidelines of the LOC network for diagnosis, treatment and follow-up.原发性玻璃体视网膜淋巴瘤：文献复习、欧洲调查结果及 LOC 网络法国诊断、治疗和随访指南
Curr Opin Oncol. 2021 Sep 1;33(5):420-431. doi: 10.1097/CCO.0000000000000776.
5
Refractory Primary Vitreoretinal Lymphoma Involving the Spinal Cord with a Temporary Complete Response to Tirabrutinib.难治性原发性玻璃体内视网膜淋巴瘤累及脊髓，替拉鲁替尼治疗暂时完全缓解。
Intern Med. 2023 Feb 1;62(3):459-463. doi: 10.2169/internalmedicine.9591-22. Epub 2022 Jul 5.
6
Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium.原发性眼玻璃体视网膜淋巴瘤：国际原发性中枢神经系统淋巴瘤协作组研讨会报告。
Oncologist. 2011;16(11):1589-99. doi: 10.1634/theoncologist.2011-0210. Epub 2011 Nov 1.
7
Long-term outcomes of combined intravitreal methotrexate and systemic high-dose methotrexate therapy in vitreoretinal lymphoma.眼内肿瘤淋巴瘤中玻璃体内甲氨蝶呤联合全身大剂量甲氨蝶呤治疗的长期疗效。
Cancer Med. 2023 Apr;12(7):8102-8111. doi: 10.1002/cam4.5609. Epub 2023 Jan 5.
8
Evidence-based expert consensus on the management of primary central nervous system lymphoma in China.中国原发性中枢神经系统淋巴瘤管理的循证专家共识。
J Hematol Oncol. 2022 Sep 29;15(1):136. doi: 10.1186/s13045-022-01356-7.
9
Primary vitreoretinal lymphoma: a diagnostic and management challenge.原发性玻璃体视网膜淋巴瘤：诊断和治疗的挑战。
Blood. 2021 Oct 28;138(17):1519-1534. doi: 10.1182/blood.2020008235.
10
Clinical features of primary vitreoretinal lymphoma developing extra-central nervous system (CNS)/testicular lymphomas with or without CNS involvement: A single-centre study of 13 cases.原发性玻璃体视网膜淋巴瘤合并或不合并中枢神经系统（CNS）受累时发生中枢神经系统外/睾丸淋巴瘤的临床特征：一项对13例患者的单中心研究
Br J Haematol. 2023 Apr;201(1):158-161. doi: 10.1111/bjh.18663. Epub 2023 Jan 24.

引用本文的文献

1
Clinical guidelines for the diagnosis and treatment of vitreoretinal lymphoma in Chinese patients (2024).中国患者玻璃体视网膜淋巴瘤诊断与治疗临床指南（2024年）
Eye Vis (Lond). 2025 May 26;12(1):20. doi: 10.1186/s40662-025-00434-4.
2
High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study.孤立性玻璃体视网膜淋巴瘤患者的大剂量化疗联合自体造血干细胞移植：一项LOC网络研究
Bone Marrow Transplant. 2025 Mar;60(3):297-304. doi: 10.1038/s41409-024-02477-y. Epub 2024 Nov 19.
3
Novel Therapies for Primary Central Nervous System Lymphomas.
原发性中枢神经系统淋巴瘤的新型治疗方法。
Curr Neurol Neurosci Rep. 2024 Dec;24(12):621-629. doi: 10.1007/s11910-024-01376-5. Epub 2024 Oct 11.
4
Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients.这是 LOC-R01 研究的 Ib 期部分，这是一个 LOC 网络非比较性随机 Ib/II 期研究，旨在测试 R-MPV 联合来那度胺或伊布替尼治疗新诊断的原发性中枢神经系统淋巴瘤（PCNSL）患者。
J Hematol Oncol. 2024 Sep 19;17(1):86. doi: 10.1186/s13045-024-01606-w.
5
[Clinicopathologic characteristics and survival analysis of primary large B-cell lymphoma of the central nervous system].[中枢神经系统原发性大B细胞淋巴瘤的临床病理特征及生存分析]
Zhonghua Xue Ye Xue Za Zhi. 2024 May 14;45(5):481-487. doi: 10.3760/cma.j.cn121090-20231126-00278.
6
Beyond Chemotherapy: Present and Future Perspectives in the Treatment of Lymphoproliferative Disorders.超越化疗：淋巴增殖性疾病治疗的现状与未来展望
Biomedicines. 2024 Apr 29;12(5):977. doi: 10.3390/biomedicines12050977.
7
Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma.为复发/难治性弥漫性大B细胞淋巴瘤制定新策略。
J Clin Med. 2023 Nov 28;12(23):7376. doi: 10.3390/jcm12237376.